Charles River Labs Unveils Pathway to Purpose Strategy at Investor Day, Targets 5-7% Revenue Growth by 2030

Charles River Laboratories International used its 2026 Investor Day on September 24 to unveil a refreshed strategic framework called Pathway to Purpose, setting long-term financial targets through 2030 and signaling that its near-term results are tracking better than expected. CEO Birgit Girshick led the presentation alongside senior management, outlining plans to modernize the company, strengthen its scientific portfolio, and enhance the client experience.

For 2026, the company reaffirmed its financial guidance and said it now expects both revenue and non-GAAP earnings per share to come in at the upper ends of their respective guidance ranges, citing continued favorable demand from biopharmaceutical clients. Organic revenue growth guidance stands at the upper end of 0% to 1%, with a non-GAAP operating margin of 21.0% to 21.3%.

Looking to 2030, Charles River introduced targets calling for organic revenue growth of 5% to 7% on a compound annual basis from 2027 through 2030 and a non-GAAP operating margin of approximately 24%, up roughly three percentage points from current guidance. The company's Apollo platform, a scientific decision-support and e-commerce tool, now serves more than 18,000 client users and was recently expanded to support Manufacturing Solutions clients, underscoring the digital modernization thread running through the strategy.

CRL shares surged on the day, outperforming competitors on what MarketWatch described as a strong trading session. Analyst sentiment had been building ahead of the event, with JPMorgan, Argus, TD Cowen, and Evercore ISI all having lifted price targets into the $300 to $330 range, pointing to improving end markets and a recovery in preclinical demand.